Abstract: Characteristic of chronic myelogenous leukemia (CML) is the presence of the chimeric p120.sup.bcr-abl protein possessing elevated protein tyrosine kinase activity relative to normal c-abl tyrosine kinase. Hematopoietic progenitors isolated from CML patients in the chronic phase contain a constitutively tyrosine phosphorylated protein that migrates at approximately 62 kDa by SDS-PAGE and associates with the p120 ras GTPase-activating protein (GAP). This novel protein, called p62.sup.dok (p62 protein downstream of tyrosine kinases), was isolated from a hematopoietic cell line expressing p120.sup.bcr-abl. Association of p62.sup.dok with GAP correlates with its tyrosine phosphorylation. p62.sup.dok is rapidly tyrosine phosphorylated upon activation of the c-kit receptor, implicating it as a component of a signal transduction pathway downstream of receptor tyrosine kinases.

Abstract: Cyclic peptides comprising three colinear amino acids, arginine-lysine-lysine (RKK) are provided that bind to the integrin .alpha.2I domain and are potent inhibitors of its interaction with collagens I and IV and laminin-1. Methods of using such peptides to block integrin function and to inhibit cell migration are also provided.

Abstract: Novel human immunoglobulin V.sub.H segments and DNA fragments containing the same are disclosed. The DNA fragment according to the present invention is the fragment having a size of about 800 kbp which is shown in FIG. 1. The human immunoglobulin V.sub.H segments according to the present invention are contained in the fragment of this DNA fragment of about 800 kbp, and there are 50 novel segments. The base sequences of these :segments are shown in the Sequence Listing. The present invention also provides DNA fragments which contain two or more of these V.sub.H segments.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for a secreted polypeptide designated zsig15. The polypeptides, and polynucleotides encoding them, may be used for mapping chromosome 19 and markers for tumor growth. The present invention also includes antibodies to the zsig15 polypeptides.

Abstract: Peptides containing regions of myelin basic protein found in the 86-102 and 143-168 sequences that are immunodominant in humans suffering from multiple sclerosis.

Abstract: The present invention relates to the use of molecules capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as diagnostic reagents for the detection of metastases in vivo. Such metastases can include, but are not limited to, micrometastases.

Abstract: A cancer prognostic having particular utility in the prognosis of head and neck squamous cell cancer, in which the expression levels of either or both of Transforming Growth Factor Alpha (TGF-.alpha.) or Epidermal Growth Factor Receptor (EGFR) are assayed directly from a sample of tumor tissue. The expression level once quantitated is normalized as to standard, and the standardized expression level is compared to the prognostic threshold of about 83% of standard for TGF-.alpha. or of about 23% of standard for EGFR, or the corresponding upper threshold of the "low" tertile regardless of how calculated. Virtually all if not all patients demonstrating this low expression level survive at least five years after initial diagnosis, assuming completion of treatment with standard surgical tumor excision and radiation protocols for squamous cell head and neck cancer. Whether an individual patient's expression levels of TGF-.alpha.

Abstract: The amino acid sequences of variable heavy and variable light domains of murine monoclonal antibody 1F7 are reported. Methods of use for products containing these sequences in the diagnosis and the treatment of HIV infection and AIDS are also described.

Abstract: A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and fusion proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins.

Abstract: tr-.alpha.llb, a soluble, truncated integrin found to be exclusively expressed in tumor cells is provided. An additional truncated integrin, tr-.beta.3, has also been found to be exclusively expressed in tumor cells. Diagnostic compositions including nucleic acid probes and antibodies and methods for detecting the presence of tr-.alpha.llb and tr-.beta.3 to identify the presence of tumor cells in a sample are also provided.

Abstract: Peptides containing immunodominant epitopes of myelin basic protein that are recognized by groups of T-cells from remitting-relapsing multiple sclerosis patients.

Abstract: The present invention provides a novel MHRII-associated protein designated MHRII-AP62 and antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits containing these antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein. The present invention also provides for a nucleic acid encoding the MHRII-AP62 protein and nucleic acid probes for use in the detection of the MHRII-AP62 protein. Further provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein by binding to the MHRII, agents that inhibit the activity of the MHRII-AP62 protein by binding to the MHRII-AP62 protein, or by binding to the nucleic acid encoding the MHRII-AP62 protein, and methods of using these agents to treat cancer and cancer causing diseases.

Abstract: Peptides are administered to individuals suffering from multiple sclerosis. The peptides contain immunodominant epitopes of myelin basic protein that are recognized by T-cells from relapsing-remitting multiple sclerosis patients, and that are contained in the 84-102 and 143-168 regions of human MBP.

Abstract: An antibody which binds to the CD30 antigen and a) inhibits the release of sCD30 from Hodgkin's disease cells, and b) does not bind to B cell non-Hodgkin's lymphomas or plasma cells. An example of such antibodies are the antibodies secreted from hybridoma cell line DSM ACC 2204. The antibodies may be used for diagnosis, or conjugated to a toxin to produce an immunotoxin.

Abstract: The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a cytokine relative to the unmodified tumor cell line, and (c) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained, wherein the tumor cell line is allogeneic and is not MHC-matched to the host. The present invention also provides a pancreatic tumor cell line, a method and medium for obtaining such a tumor cell line, and a composition comprised of cells of a purified pancreatic tumor cell line.

Abstract: The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.

Abstract: The invention provides a method to prevent or ameliorate hyperacute or acute rejection of a human donor organ transplanted to a human recipient. Hyperacute rejection would normally occur after a human subject receives a transplanted human organ against which the subject has preformed anti-HLA antibodies. Acute rejection occurs when the recipient of a human organ forms antibodies against that organ after transplant. The invention method comprises passing the plasma of the recipient over a sterile and pyrogen-free column coupled to anti-human immunoglobulin antibodies which bind to and remove a significant portion of the immunoglobulin from the subject's plasma.

Abstract: The present invention relates to peptides and polypeptides derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls:X-His-Asn-Pro-Yin which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.

Abstract: A novel protein associated with multidrug resistance in living cells and capable of conferring multidrug resistance on a cell is disclosed. Nucleic acids encoding the novel multidrug resistance protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel multidrug resistance protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as DAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.